Key points

In infants

• The mandatory meningococcal ACWY vaccination, which was introduced on January 1, 2025, for infants following an increase in cases of invasive meningococcal infections of types W and Y, has resulted in high vaccination coverage, with nearly 90% of infants born in 2025 having received the first dose of the ACWY meningococcal vaccine.
• Among children born in 2024, before the replacement of the meningococcal C vaccine with the ACWY vaccine, 79% had received at least one dose of the tetravalent ACWY meningococcal vaccine by the age of 21 months. This vaccination coverage is lower than that estimated in 2024 for meningococcal C.
• Vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year mandatory vaccination against meningococcal B was implemented for infants up to age 2, vaccination coverage increased significantly: 68% of infants born in 2024 (aged 21 months) are up to date on their vaccinations, compared to 58% in 2024.
• Vaccination coverage for other mandatory infant vaccinations is generally high, with levels close to the 95% target set by the World Health Organization (WHO).
• Given the resurgence of measles in France since 2024, it is important to note that vaccination coverage for the two doses against measles, mumps, and rubella must exceed this target in order to interrupt the circulation of the virus, which causes serious complications and even death in vulnerable individuals.
  Verifying and updating this vaccination status is essential, both for children and young adults.

Among adolescents and young adults

• Given the potential severity and increased frequency of invasive meningococcal infections during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults.
• In 2025, only 17% of 11- to 14-year-olds and 8% of 15- to 24-year-olds had received a dose of this vaccine—rates close to the national average but still far too low.
• Vaccination against meningococcal ACWY must therefore be strengthened in this age group. Its inclusion in middle school vaccination campaigns starting in 2026 should help improve protection for young people against these infections.
• Efforts must continue to increase vaccination coverage, achieve herd immunity, and reduce the circulation of meningococcal bacteria throughout the population.
• Vaccination coverage against human papillomavirus (HPV) infections continues to increase: 53% of 16-year-old girls and 34% of 16-year-old boys have completed the vaccination series.
• The coverage gap between girls and boys continues to narrow. This progress is encouraging, but remains insufficient to significantly reduce the incidence of cancers linked to these infections.
• The national goal is to achieve 80% vaccination coverage among girls and boys by 2030. Efforts must continue, particularly through vaccination campaigns in middle schools and by strengthening information on the importance of vaccinating boys.
• Vaccinating boys is just as essential as vaccinating girls: it contributes to equitable and sustainable protection.

Vaccination Uptake

Vaccination uptake remains high in the region, particularly among young people.
According to the 2024 Santé publique France Barometer, 86% of 18- to 25-year-olds say they are in favor of vaccination, a level higher than the national average (83%).